2/3상모집 중단 (진행 중)
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
연구 개요
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive/clinical impairment or improves disease-related biomarkers.
- 스폰서
- 협력: 일라이 릴리, 로슈
- 적응증
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- 중재
- Gantenerumab, Solanezumab, Matching Placebo (Gantenerumab), Matching Placebo (Solanezumab), Gantenerumab, E2814, Lecanemab, Matching Placebo (E2814)
- 목표 등록
- 490명
- 시작일
- 2012-12-01
- 완료(예정)
- 2028-07-01
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.